Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
Richard
Coker
;
(2002)
Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
The international journal of tuberculosis and lung disease, 6 (8).
pp. 649-650.
ISSN 1027-3719
https://researchonline.lshtm.ac.uk/id/eprint/17607
Item Type | Article |
---|---|
Keywords | Antitubercular Agents/*therapeutic use, *Communicable Disease Control/economics, Cost-Benefit Analysis, Costs and Cost Analysis, Human, Tuberculosis, Multidrug-Resistant/*drug therapy |
ISI | 177114800002 |
Date Deposited | 17 Oct 2011 22:46 |